PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Cancer Res. Author manuscript; available in PMC 2010 May 15.
Published in final edited form as:
PMCID: PMC2710962
NIHMSID: NIHMS111605

Identification of PDE4D as a proliferation promoting factor in prostate cancer using a Sleeping Beauty transposon based somatic mutagenesis screen

Abstract

Retroviral and transposon-based mutagenesis screens in mice have been useful for identifying candidate cancer genes for some tumor types. However, many of the organs that exhibit the highest cancer rates in humans, including the prostate, have not previously been amenable to these approaches. This study demonstrates for the first time that the Sleeping Beauty transposon system can be used to identify candidate prostate cancer genes in mice. Somatic mobilization of a mutagenic transposon resulted in focal epithelial proliferation and hyperplasia in the prostate. Efficient methods were established to identify transposon insertion sites in these lesions, and analysis of transposon insertions identified candidate prostate cancer genes at common insertion sites, including Pde4d. PDE4D was also over-expressed in human prostate cancer patient samples and cell lines, and changes in PDE4D mRNA isoform expression were observed in human prostate cancers. Furthermore, knockdown of PDE4D reduced the growth and migration of prostate cancer cells in vitro, and knockdown of PDE4D reduced the growth and proliferation rate of prostate cancer xenografts in vivo. These data indicate that PDE4D functions as a proliferation promoting factor in prostate cancer, and the Sleeping Beauty transposon system is a useful tool for identifying candidate prostate cancer genes.

INTRODUCTION

Forward somatic mutagenesis screens using murine retroviruses as insertional mutagens have been effective tools for cancer gene discovery in mammary tumors, hematopoietic neoplasms, and brain tumors in mice (13). However, many tissue types that are commonly transformed into tumors in humans are not affected by known retroviruses. Two studies have shown that genome-wide somatic mutagenesis using the Sleeping Beauty (SB) transposon system can be used to induce tumors and identify cancer genes for hematopoietic tumors and sarcomas (4, 5). Candidate cancer genes were identified in these studies by finding sites in the genome of SB-induced tumors that were recurrently mutated by transposon insertions in multiple independent tumors. Such sites are called common insertion sites (CISs), and past experience with retroviral-based and transposon-based screens has shown that the genes located at CISs act as oncogenes or tumor suppressors. A major unresolved question for this approach is whether or not SB will be more broadly applicable for cancer gene discovery in epithelial cancers which are responsible for 80% of human cancer deaths (6).

Prostate adenocarcinoma is the most commonly diagnosed male cancer and is one of the leading causes of male cancer death (6). Prior to the development of invasive adenocarcinoma, several histologic abnormalities can sometimes be observed that are considered potential precursor lesions for prostatic adenocarcinoma. These include prostatic intraepithelial neoplasia (PIN), atypical small acinar proliferation (ASAP), and proliferative inflammatory atrophy (PIA) (7, 8). Features associated with one or more of these candidate precursor lesions include focal areas of increased proliferation, stratification of the epithelium, loss of basal cells, and changes in nuclear morphology. Several genetic and gene expression alterations have been identified as common events in early prostate cancers. The transcription factor Nkx3.1 is commonly lost in early stage tumor epithelial cells, including loss in 20% of high grade PIN cases examined (9). This loss of expression is likely due to heterozygous deletions of the genomic locus and epigenetic silencing mechanisms (10). Recurrent deletions and translocations that create fusion genes involving transcription factors ERG, ETV1, or ETV4 in prostate epithelial cells have been reported to occur in a majority of prostate cancers, and are also detected as early as PIN (1113). Although these genetic alterations clearly play a role in early prostate cancers, the genetic basis for prostate cancer initiation remains poorly understood (14). In this study, transposon-based somatic mutagenesis caused foci of altered histology and elevated proliferation in the prostatic epithelium that resembled features associated with prostate cancer precursor lesions. Analysis of transposon insertion sites in these lesions identified candidate cancer genes that may play a role in prostate cancer initiation, including PDE4D. PDE4D was also over-expressed in human prostatic adencarcinomas, and shRNA knockdown of PDE4D reduced the proliferation of prostate cancer cells in vitro and in vivo, supporting its potential role as a proliferation promoting factor in human prostate cancer.

MATERIALS AND METHODS

Mice

The mouse strains utilized for this study have previously been described including CAGGS-SB10 transgenic, Rosa26-SB11 knock-in, and low-copy T2/onc transgenic (4, 5).

Immunohistochemistry

Tissues were stained for the Ki67 antigen as previously described (15). A modified staining protocol was used for laser capture microscopy as follows: tissues were dissected into cold PBS, embedded directly into Tissue Freezing Medium (Triangle Biomedical Sciences) and stored at −80°C. Tissue sections (5µm) were cut at −20°C with a cryostat and immediately mounted onto PEN membrane slides (Leica) and air-dried for 30 minutes followed by fixation in 100% ethanol at −20°C. Slides were washed with PBS, blocked with 2.5% sheep serum in PBS, stained for 3 hours with anti-phospho-Histone-H3 (Upstate Cell Signaling Solutions) 1:150 in 2.5% sheep serum in PBS, and washed in PBT (PBT = 1X PBS with 0.1% Tween 20). The primary antibody was visualized with an anti-rabbit IgG horseradish peroxidase conjugate (Chemicon) diluted 1:500 in 2.5% sheep serum in PBS followed by PBT washes and staining with the DAB reagent (Vector Laboratories) according to the manufacturer’s instructions. Slides were counter stained with Hematoxylin, dehydrated into 100% ethanol, and air dried for 1 hour prior to laser capture.

Laser capture microscopy and Liner-mediated PCR

Cells of interest were captured from tissue sections using a Leica LMD6000 laser capture microdisection microscope. DNA was isolated from the captured cells using a Qiagen Qiamp DNA Micro Kit according to the manufacturer’s instructions except GenomiPhi DNA amplification sample buffer was substituted for the Qiagen elution buffer during the last step of DNA purification. Samples were then amplified using the GenomiPhi DNA Amplification Kit (GE Healthcare) according to the manufacturer’s instructions. Transposon-genomic DNA junctions were amplified as previously described (16), cloned into plasmids, and sequenced by Functional Biosciences Inc.

AQUA Analysis of PDE4D expression

The AQUA analysis was conducted on a previously assembled tissue microarray (TMA) of prostate tissues from patients treated at the University of Wisconsin-Madison using an established protocol (17). Epithelial compartment visualization was achieved with a 30 minute incubation of a mouse anti-cytokeratin AE1/AE3 1:200 (Dako North America, Carpinteria, CA) and mouse anti-E-cadherin 1:50 (Abcam, Cambridge, MA) cocktail, followed by a 30 minute incubation of Invitrogen Alexa Fluor 555 donkey anti-mouse IgG 1:200. Goat anti-PDE4D IgG 1:100 (Santa Cruz, Santa Cruz, CA) was preincubated with PDE4D protein (5x wt:wt) (Santa Cruz, Santa Cruz, CA) for 2 hr 30 min. prior to application. Both PDE4D antibody 1:100 and PDE4D with 5x protein were incubated for 60 minutes followed by a 15 minute incubation with Invitrogen biotinylated swine anti-goat IgG 1:200. Staining on the TMA was visualized as previously described (17). There were 336 tissue cores from 168 patients (2 cores from each patient) in the TMA stained for this study. In addition to an automated image acquisition and analysis as previously described (18), all cores for this study were examined for staining and morphology by surgical pathologist, Wei Huang, MD. TMA cores without sufficient epithelium (<5%) or with poor staining quality (i.e., section folding, excess trapping of fluorochrome, etc.) were excluded from analysis. In total, 282 of the 336 cores stained for PDE4D passed this quality control and were included in the final data set.

RLM-5’-RACE

The RNA analyzed in the RLM-5’-RACE experiment was isolated from human prostate samples obtained by the University of Minnesota Cancer Center Tissue Procurement Facility (TPF). For the study, prostate tissue samples were bisected. One piece was provided to our laboratory as a fresh sample that was used for the isolation of RNA. The adjacent piece of tissue was retained by the TPF for examination by a TPF staff pathologist who provided us with a pathology report that indicated the presence/absence and pathological grade of prostate cancer in each tissue sample. RNAs were analyzed using the FirstChoice RLM-RACE kit (Ambion) according to the manufacturer’s instructions. The PDE4D outer and inner primers were 5-TAGGCCACATCAGCATGGTAATGGTCT-3’ and 5’-ACCACTAGTTCACATCTTCTAGTTCCTTGGCAAGGA respectively.

Cell Culture

DU145-derived cell lines were grown in 1xRPMI (Invitrogen Gibco) supplemented with 5% activated charcoal USP (Sigma) treated fetal bovine serum (Hyclone), 100µg/ml antibiotic/antimycotic (Invitrogen Gibco), and 10−8M 5α-androsten-17β-ol-3-one (Sigma). PC3-derived cell lines were grown in 1xMEM (Invitrogen Gibco) supplemented with 5% activeated charcoal USP (Sigma) treated fetal bovine serum (Hyclone), 100µg/ml antibiotic/antimycotic (Invitrogen Gibco), 1xNon-essential amino acids (Invitrogen Gibco), and 1xSodium Pyruvate (Invitrogen Gibco). All cell lines were grown at 37°C in 5% CO2. Stable PDE4D shRNA knockdown and scrambled sequence shRNA control cell lines were generated using lentiviral transduction with shRNAs from Open Biosystems. Cells were transduced at a multiplicity of infection of 10 following manufacturers protocol and then underwent G418 selection for stable integrants. Immunoblots of cell line extracts were conducted as previously described (15) using the anti-PDE4D antibody (Abcam) diluted 1:1500 in 2.5% milk.

Growth Assays

Cells were plated at an initial density of 5,000 cells/cm2 on 4-well plates (Costar). After the growth period, cells were trypsinized, neutralized in media, and trypan blue was added. The number of viable cells was determined by counting the number of cells that exclude trypan blue on a hemacytometer. Alternatively, cells were plated at an initial density of 500 cells per well on a 96 well plate in triplicate, and cell viability was evaluated using an MTS assay (the CellTiter96 Aqueous One Solution Cell Proliferation Assay from Promega) according to the manufacturer’s instructions.

Xenograft assay

Cultured cells were trypsinized, resuspended at 106 cells in 500µl of Matrigel (BD Biosciences 356230), and injected subcutaneously into CD-1 nu/nu mice. After 1 month, xenografts were fixed in formalin and processed for IHC. Following Ki67 staining, 8 random 20X fields were photographed and the ratio of Ki67 positive nuclei to total nuclei was determined using a previously described computer-assisted method for image analysis (19).

RESULTS

Focal hyperplasia in the prostatic epithelium of transposon mutagenized mice

Previous studies showed that two mouse strains with active transposition of a mutagenic transposon, T2/onc, became moribund due to the formation of tumors with a limited tissue distribution (4, 5). The two strains used in these experiments differed in the transgene driving transposase expression (CAGGS-SB10 or Rosa26-SB11). In addition, the CAGGS-SB10;T2/onc mice were null for the Arf tumor suppressor gene. We examined the morphology and histology of prostate glands from CAGGS-SB10;T2/onc low-copy;Arf-/- mice, and the only prostatic abnormalities identified were infrequent sarcomas (data not shown). We also evaluated Rosa26-SB11;T2/onc low-copy (approximately 25 copies of T2/onc) mice. Unlike the previously reported high rate of embryonic lethality in Rosa26-SB11;T2/onc high-copy (148+ copies of T2/onc) mice (4), the ratio of Rosa26-SB11;T2/onc low-copy mice to single transgenic littermates was consistent with little or no embryonic lethality. However, these mice succumbed to tumor formation, primarily leukemias, with an median latency of 6–7 months (Lara Collier, unpublished observation). Examination of the histology of prostate glands from moribund Rosa26-SB11;T2/onc low-copy mice revealed focal areas of epithelial hyperplasia in the anterior prostate (data not shown) and dorsolateral prostate (Supplemental Fig. 1A, B). Immunohistochemistry (IHC) suggested that the difference in prostatic phenotype for the two models could be explained by differences in transposase expression in the prostate gland (Supplemental Fig. 2).

The prostates of Rosa26-SB11;T2/onc low-copy mice were also evaluated using proliferation markers Ki67 (20) and phospho-(ser10)-histone H3 (21). In single transgenic control prostates (Rosa26-SB11 or T2/onc low-copy only), Ki67 positive cells were rare and typically found as single positive cells or a pair of positive cells (Supplemental Fig. 1C–D). In contrast, Rosa26-SB11;T2/onc low-copy double transgenic mice contained focal areas with many Ki67 positive cells (Fig. 1). A quantitative analysis of the distribution of Ki67 positive cells confirmed the increased clustering of Ki67 positive cells into focal areas of elevated proliferation in Rosa26-SB11;T2/onc low-copy prostates relative to controls (Fig. 2A). In addition to the change in the distribution of proliferating cells, an overall increase in the number of proliferating prostatic epithelial cells was observed in Rosa26-SB11;T2/onc low-copy mice with both Ki67 and phospho-(ser10)-histone H3 (data not shown).

Figure 1
Focal areas of elevated proliferation in the prostates of Rosa26-SB11;T2/onc mice
Figure 2
Analysis of proliferating prostatic lesions in Rosa26-SB11;T2/onc low-copy mice

Identification of transposon insertion sites in prostatic hyperplasia

After failed initial attempts to identify transposon insertion sites present in the prostatic lesions using laser capture microscopy, the limits of the published linker-mediated PCR (LM-PCR) method (4, 5) were evaluated using DNA from two mice with well characterized transposon insertions inherited through the germline (22). These mice lacked transposase expression so all somatic cells from each animal harbored identical transposon insertions. LM-PCR on serial dilutions of high quality DNA showed that the isolation of transposon-flanking sequences became unreliable in the low-ng range (Fig. 2B). A modified protocol (see Materials and Methods) allowed the reliable identification of the known transposon insertion sites from approximately 100 laser captured cells isolated from these animals (data not shown). When this protocol was used to identify the transposon insertion sites present in foci of proliferation (clusters of 3 or more phospho-ser10-histone H3 positive cells) from Rosa26-SB11;T2/onc low-copy prostates, complex banding patterns were observed following LM-PCR that varied from sample to sample (Fig. 2C).

In order to identify genes that can initiate proliferation/hyperplasia in the prostatic epithelium, 100 proliferating clusters of prostatic epithelial cells were laser captured from the prostates of 20 transposon-mutagenized mice on an otherwise wild type genetic background (median animal age 6 months), and 85 proliferating clusters of prostatic epithelial cells were captured from the prostates of 17 transposon mutagenized mice deficient for Arf (median animal age 11 weeks). The laser-captured lesions were analyzed by LM-PCR, and the LM-PCR products were sequenced to determine the transposon insertion sites. Unique genomic sequences were mapped back onto the mouse genome using the mouse genome database maintained by the Wellcome Trust Sanger Institute at www.ensembl.org. This analysis identified 77 unique insertions isolated from prostatic lesions generated by mutagenesis on a wild type genetic background and 27 unique insertions isolated from prostatic lesions generated by mutagenesis on the Arf-null background. Insertions were distributed across most mouse chromosomes (Fig. 2D). The two chromosomes that harbored T2/onc concatomers in the experiment (chromosomes 1 and 15) had an increased frequency of insertions that was expected due to the tendency of transposons to mobilize at higher frequency to locations linked to the donor transposon concatomer (23), a phenomenon called local hopping. The prostate insertions were evaluated using previously proposed criteria for CIS identification (24). Using these criteria, 3 CISs were found in the prostate data set. The three genes at prostate CISs in the experiment were Rabgap1l, Pde4d, and Klhl13 (Supplemental Table 1). Rabgap1l is known to be located very close to the chromosome 1 T2/onc donor concatomer (5). Consequently, this gene may have been repeatedly mutated due to local hopping. The other two genes located at CISs were not linked to the T2/onc concatomers utilized in the experiment so mutation of these genes likely contributed to the abnormal proliferation observed in the prostatic epithelium. Insertions in Pde4d were observed in proliferating lesions isolated from three independent mice. However, all of the insertions were in intron 5 with the MSCV promoter in T2/onc oriented toward exon 6 of Pde4d. Pde4d encodes several alternatively spliced transcripts including short-isoform transcripts that initiate translation at an in-frame AUG codon with a strong Kozak consensus located in exon 6 (Fig. 3). Thus, the T2/onc insertions would be predicted to cause over-expression of one or more endogenous short isoforms of Pde4d in prostatic epithelial cells. Transposon insertions in Klhl13 were observed in both promoter orientations.

Figure 3
Transposon insertion sites in PDE4D

The prostate insertion sites observed in this experiment were also compared to previously reported retroviral and transposon insertions from other cancer screens by searching the Retroviral Tagged Cancer Gene Database [RTCGD; (25)]. Both Rabgap1l and Pde4d have been previously observed as CISs in other somatic mutagenesis screens for cancer genes (5, 26) while Klhl13 is a novel CIS. Since many oncogenes and tumor suppressor genes function in multiple tumor types, we hypothesized that the combined prostate and RTCGD data sets may identify new CISs. Using the criteria proposed by Mikkers et al. (24) for the approximately 8700 insertions in the combined data sets, five novel CISs were identified (Supplemental Table 2). Among the remaining insertion sites isolated from prostatic lesions, eleven were insertions into genes previously reported as CISs (Supplemental Table 3).

Overexpression and mRNA isoform changes for PDE4D in human prostate cancer

To investigate the possibility that PDE4D is involved in human prostate cancer, we collaborated with the laboratory of a board-certified surgical pathologist, Wei Huang, MD. The Huang laboratory had previously assembled a tissue microarray (TMA) of prostate tissues from patients treated at the University of Wisconsin-Madison including patients with benign prostatic hyperplasia (BPH) and patients with prostatic adenocarcinoma (17). The approach used for analyzing PDE4D protein expression on the TMA was a previously described method (18) for automated quantitative analysis (AQUA). For the AQUA approach, proteins were detected using fluorescence-based immunohistochemistry. The TMA was co-stained with the antibody against PDE4D, an epithelial cytoplasm-specific antibody cocktail (E-cadherin and anti-cytokeratin antibodies), and a nuclear stain (DAPI). The stained TMA was then imaged using a series of fluorescent filters corresponding to each stain, and the images were analyzed using previously developed algorithms (18) to determine relative expression levels of PDE4D. A parallel TMA was analyzed in which the anti-PDE4D antibody was blocked with a PDE4D peptide to confirm specificity of the PDE4D signal. A strong PDE4D-specific signal was observed for the PDE4D antibody that co-localized with the E-cadherin/cytokeratin stains in human prostatic adenocarcinomas (Figure 4A). The prostate TMA cores from patients with prostatic adenocarcinoma varied in pathological grade (as scored by surgical pathologist Wei Huang, MD) and included cores that were primarily composed of non-invasive epithelial cells (normal or PIN), cores that were primarily invasive cancer, and cores from sites of metastasis. When the AQUA data was quantified and stratified by these pathologic features, all prostate tissues from patients with adenocarcinomas had higher PDE4D expression than tissues from patients with BPH (Figure 4B). No significant differences in PDE4D expression level were observed among the different pathological grades for tissue cores from prostate cancer patients. PDE4D expression in prostate cancer was also evaluated by immunoblotting in normal primary prostatic epithelial cells and 5 common prostate cancer epithelial cell lines. PDE4D protein expression was increased in the human prostate cancer cell lines compared to normal primary prostatic epithelial cells (Supplemental Fig. 3).

Figure 4
PDE4D is overexpressed and has altered mRNA isoform expression in human prostate cancer patient samples

To further understand the expression of PDE4D in human prostate cancer, pooled RNA from samples of pathologically normal prostate and prostatic adenocarcinomas were evaluated by RNA ligase-mediated 5’ Rapid Amplification of cDNA Ends [RLM-5’-RACE; (27)]. The predominant RLM-5’-RACE products from normal prostate and prostate cancer RNAs were distinct (Fig. 4C), suggesting altered PDE4D isoform expression in human prostate cancer. Sequencing of the predominant RLM-5’-RACE product obtained from the pooled prostatic adenocarcinoma RNA identified a cDNA with a first exon that began at base pair 349 of the Genbank deposited sequence for the PDE4D5 isoform (accession AF12073.1) and was spliced to exon 2 of PDE4D in a manner identical to the other PDE4D long isoform transcripts.

PDE4D knockdown reduces the growth rate of human prostate cancer cells and xenografts

As an initial test of the functional role of PDE4D in prostate cancer cells, PDE4D protein expression was reduced in DU145 and PC3 cells using three different shRNAs targeting sequences in PDE4D (Fig 5). Based on densitometry of immunoblots with an anti-PDE4D antibody, these shRNAs achieved 70–97% knockdown of PDE4D protein expression (data not shown). In all cases, the knockdown cell populations had significantly reduced in vitro growth rates compared to control cells with stable transfection of scrambled sequence shRNAs (Fig. 5A–C). The impact of PDE4D knockdown on cell migration was also evaluated using an in vitro wound healing assay, and PDE4D knockdown significantly decreased the migration rate of DU145 cells (Supplemental Fig. 4).

Figure 5
PDE4D shRNA knockdown reduces prostate cancer cell growth

To further evaluate the role of PDE4D in prostate cancer cells, we used the exon 14/15 PDE4D knockdown and scrambled shRNA control DU145 cell lines in a xenograft model. PDE4D knockdown resulted in smaller xenografts compared to control tumors (Fig. 6A; Supplemental Fig. 5A). The reduction in wet weight of the PDE4D knockdown xenografts was statistically significant, but there was considerable variability in wet weight among the xenografts in each group due to the presence of large cysts lacking viable tumor cells in many of the xenografts (Supplemental Fig. 5B–D). Consequently, we also assayed tumor cell proliferation using immunostaining for the Ki67 antigen. Analysis of the Ki67 labeling index for PDE4D knockdown and control xenografts found a statistically significant 39.0% reduction (p<0.01, by T-Test) in the Ki67 labeling index for knockdown tumors relative to controls (Fig. 6B–D) indicating a reduced proliferation rate in response to PDE4D knockdown. We also examined apoptosis in the xenografts using a TUNEL assay. While moderate rates of apoptosis were observed in all xenografts, no significant differences were observed between the control shRNA and PDE4D knockdown tumors (data not shown) suggesting that the reduction in tumor size was primarily due to decreased proliferation in response to PDE4D knockdown.

Figure 6
PDE4D knockdown reduces the growth of DU145 cells in vivo

DISCUSSION

Genetic screens in model organisms have been an important strategy for understanding the molecular genetics of several cancers. For many years, one of the most productive screening approaches has been the use of slow transforming retroviruses as insertional mutagens to tag and identify endogenous oncogenes and tumor suppressor genes in mice [reviewed in (28)]. Screens using retroviruses have investigated several tumor types including mammary tumors, hematopoietic neoplasms, and brain tumors. These screens have identified genes and genetic interactions that have proven to be directly relevant for understanding the equivalent human cancers. One of the major limitations of retroviruses as a screening tool is their cell-type specificity that defines the types of tumors they can induce. This has prevented retroviral-based screens for many of the most common tumor types in humans.

Recently, the SB transposon system has been shown to function as an insertional mutagen to discover cancer genes for hematopoietic tumors, medulloblastomas, and sarcomas in genetically modified mice (4, 5). These initial proof-of-principle studies showed that mobilization of transposons engineered to have gain- and loss-of-function elements could accelerate tumor formation, and cloning transposon insertion sites identified candidate cancer genes at CISs. Transposon-based screening has great potential because mobilization of the transposon is not cell-type restricted so screens are possible in tissues not amenable to retroviral screens such as the sarcomas investigated by Collier, Carlson et al. However, it had previously not been determined if transposon-based screens can be used to investigate epithelial tumors that constitute the majority of human cancers. In addition, although the candidate cancer genes at the CISs observed by Dupuy et al. and Collier, Carlson et al. included genes not previously implicated in cancer, it is not yet clear whether these candidate cancer genes will prove to be relevant for understanding disease processes in humans.

The current study addresses these issues by investigating transposon-mutagenized mice for prostate cancer related phenotypes. The prostates of Rosa26-SB11;T2/onc low-copy mice had focal areas of epithelial hyperplasia and elevated epithelial proliferation that resembled features of prostate cancer precursor lesions. Cloning transposon insertion sites from these lesions identified candidate cancer genes at transposon CISs. We conducted our screen using both wild type and Arf-null genetic backgrounds. Insertions were observed at newly identified and previously known CISs on both genetic backgrounds. Based on the CISs in the Retroviral Tagged Cancer Gene Database (25), about 2.2% of all genes have been identified as CISs in one or more cancer screens. For our screen, 19% of insertions on a wild type genetic background were into CIS genes reflecting a 9-fold enrichment over what would be predicted by chance. For insertions on the Arf-null background, 41% of insertions were into CIS genes reflecting a 19-fold enrichment over what would be predicted by chance. These data suggest that most of the insertions into CIS genes in our screen were likely to be selected insertions that contributed to the focal prostate epithelial hyperplasia and proliferation observed in Rosa26-SB11;T2/onc low-copy mice. Further investigation of one of the CIS genes, Pde4d, showed that it is a mitogenic factor for prostatic epithelial cells that is also over-expressed in human prostate cancers. Thus, transposon-based screens in mice can discover novel genes that are directly relevant for understanding human prostate cancer.

PDE4D is a gene encoding several phosphodiesterase enzymes that cleave cAMP and are expressed in multiple tissues (2934). PDE4D encodes at least nine protein isoforms that all possess the phosphodiesterase catalytic domain in the C-terminus but differ at the N-terminus. The nine isoforms are categorized into two groups: long isoforms (3, 4, 5, 7, 8, 9) and short isoforms (1, 2, 6). In our study, we identified multiple transposon insertions into the mouse Pde4d gene that are predicted to cause overexpression of one or more short isoforms. A previous investigation of rats that had increased susceptibility to prostate carcinogenesis due to developmental exposure to estrogens found increased expression of PDE4D4, one of the long isoforms, in the prostates of susceptible rats (35). This led the authors to hypothesize that PDE4D overexpression had a causal role in prostate cancer susceptibility in the rat model. Our finding that PDE4D protein is overexpressed in the prostatic epithelial cells of patients with prostatic adenocarcinoma relative to patients with the benign disease BPH regardless of the histopathology of the epithelial cells in the adenocarcinoma patients (normal, PIN, invasive cancer, metastasis) suggests PDE4D overexpression in the aging human prostate may also be a permissive event that increases susceptibility to prostate cancer.

The status of PDE4D in human prostate cancer had not previously been specifically investigated, but genome-wide expression profiling studies of human prostate cancer often included probes against PDE4D transcripts. We reviewed PDE4D for expression changes in the available prostate cancer expression profiling studies using the Oncomine Database (36). The available expression profiling studies generally observed no change for PDE4D mRNA expression or a decrease in expression with increasing pathologic grade of prostate cancer. The potential discrepancy between our finding of an increase in PDE4D protein expression in prostate cancer patients and the decreased PDE4D mRNA expression observed in some expression profiling studies may reflect post-transcriptional regulation of PDE4D. Comprehensive side-by-side analyses of mRNA and protein expression for multiple PDE4D isoforms in the rat have found a poor correlation between mRNA and protein expression levels for multiple PDE4D isoforms. This has led to the hypothesis that these PDE4D isoforms are post-transcriptionally regulated (31). A more dramatic finding in our study was a shift in PDE4D isoform usage in prostate cancer that we identified in RLM-5’-RACE experiments (Fig. 4C, D). The RLM-5’-RACE protocol includes ligation of an RNA adaptor to mRNAs prior to reverse transcription in a reaction that requires the presence of a 7-methylguanosine cap at the 5’-terminus of the mRNA (27). This allows RLM-5’RACE to selectively amplify full-length cDNA 5’-ends. We infer from our data that the predominant PDE4D transcript in prostatic adenocarcinomas is initiated at base pair 349 of the Genbank deposited sequence for the PDE4D5 isoform (accession AF12073.1). Transcripts initiated at this location would not include the normal translation initiation codon for the published PDE4D5 transcript and would presumably initiate translation at one of the in frame AUG codons present in the truncated mRNA transcript. This possibility is consistent with the size of the PDE4D protein bands observed by immunoblot in prostate cancer cell lines (Supplemental Fig. 3).

Collectively, the increased expression of PDE4D and altered isoform usage in prostate cancer cells indicate that there will be lower cAMP levels in at least some sub-cellular compartments of prostate cancer cells relative to normal prostatic epithelial cells. This correlates with previous in vitro studies in prostate cancer cell lines that have found that increasing levels of cAMP by stimulating adenylate cyclase with Forskolin, using cAMP analogs, or treatment with general PDE inhibitors led to growth arrest and apoptosis of prostate cancer cell lines (3739). Our data that selectively targeting PDE4D with shRNAs also limits prostate cancer cell growth suggests that future studies with PDE4D selective inhibitors as potential anti-prostate cancer agents are warranted.

Considered more broadly, pharmacologic inhibition of the PDE4 family of enzymes induces apoptosis or inhibits growth in a variety of cancer cell types. However, the role of PDE4D specifically in human cancer has not been widely investigated. PDE4 family inhibition induces apoptosis in Chronic Lymphocytic Leukemia (CLL) cells (40). However, this effect may not be due to PDE4D specifically, as PDE4D mRNA expression was found to be lower in CLL cells than in normal peripheral blood mononuclear cells (41). Analysis of genomic copy number changes in human lung adenocarcinoma has detected homozygous deletions at the PDE4D locus (42). Similar studies on esophageal adenocarcinoma identified both homozygous deletions and loss of heterozygosity at the PDE4D locus (43), implicating PDE4D as a tumor suppressor gene in these two tumor types. As regulation of PDE4D activity is complex, close examination of its genomic sequence, transcriptional regulation, alternative splicing and other post-transcriptional/translational modifications will be necessary to address the contribution of PDE4D to tumor formation in humans. In addition, it is possible that the ability of PDE4D to enhance or limit tumor growth may be cell type dependent, a phenomenon that has been observed for other cancer genes such as NOTCH1 (44).

Prostate cancer is the most common cancer in men (6) and there is considerable genetic heterogeneity among individual prostate cancers (14). Transposon-based somatic mutagenesis is a promising strategy for uncovering the genetically diverse ways that prostate tumors can evolve. This study refined the methodology for transposon-based screening to allow investigation of small lesions that resembled the initial steps of prostate cancer progression. This identified Pde4d as a proliferation promoting factor in the prostates of mice and humans. In addition to Pde4d, this study identified 18 other genes as candidate prostate cancer genes including genes at CISs in the prostate data set (Supplemental Table 1), genes at CISs for the combined prostate + RTCGD data sets (Supplemental Table 2), and prostate insertions at genes that had previously been identified as CISs (Supplemental Table 3). Among the 19 candidate prostate cancer genes identified in our study were 5 genes that have previously been investigated for their potential roles in prostate cancer including Dpt, Notch1, Runx3, Igf1r, and Ghr [representative studies: (4549)]. The remaining 14 candidate prostate cancer genes have not previously been investigated for their potential roles in prostate cancer. Future studies are anticipated to include evaluation of these genes in human prostate cancers and additional screening for candidate cancer genes using the refined methods developed for this study.

Supplementary Material

Suppl Information

ACKNOWLEDGEMENTS

We thank M. Roussel for the Arf-null mice and A. Dupuy, N. Copeland and N. Jenkins for the Rosa26-SB11 mice. We thank Erin Riley for technical assistance on the project.

Financial Support: This study was supported by award W81XWH-05-1-053 (proposal PC050617) to PCM from the Department of Defense Congressionally Mandated Research Program, grant AG024278 to PCM from the NIH/NIA, and grant CA118600 to DAL from the NCI/NIH. LSC was supported by postdoctoral fellowship PF-05-153-01 (MGO) from the American Cancer Society and by CA122183 from the NCI/NIH. EPR and SLK were supported by training grant CA09138 from the NCI/NIH.

REFERENCES

1. Jonkers J, Berns A. Retroviral insertional mutagenesis as a strategy to identify cancer genes. Biochim Biophys Acta. 1996;1287:29–57. [PubMed]
2. Johansson FK, Brodd J, Eklof C, et al. Identification of candidate cancer-causing genes in mouse brain tumors by retroviral tagging. Proc Natl Acad Sci U S A. 2004;101:11334–11337. [PubMed]
3. Callahan R, Smith GH. MMTV-induced mammary tumorigenesis: gene discovery, progression to malignancy and cellular pathways. Oncogene. 2000;19:992–1001. [PubMed]
4. Dupuy AJ, Akagi K, Largaespada DA, Copeland NG, Jenkins NA. Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature. 2005;436:221–226. [PubMed]
5. Collier LS, Carlson CM, Ravimohan S, Dupuy AJ, Largaespada DA. Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature. 2005;436:272–276. [PubMed]
6. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106–130. [PubMed]
7. Schlesinger C, Bostwick DG, Iczkowski KA. High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation: predictive value for cancer in current practice. Am J Surg Pathol. 2005;29:1201–1207. [PubMed]
8. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol. 1999;155:1985–1992. [PubMed]
9. Bowen C, Bubendorf L, Voeller HJ, et al. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res. 2000;60:6111–6115. [PubMed]
10. Asatiani E, Huang WX, Wang A, et al. Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer. Cancer Res. 2005;65:1164–1173. [PubMed]
11. Tomlins SA, Mehra R, Rhodes DR, et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 2006;66:3396–3400. [PubMed]
12. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644–648. [PubMed]
13. Cerveira N, Ribeiro FR, Peixoto A, et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia. 2006;8:826–832. [PMC free article] [PubMed]
14. Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. Genes Dev. 2000;14:2410–2434. [PubMed]
15. Kuslak SL, Marker PC. Fibroblast growth factor receptor signaling through MEK-ERK is required for prostate bud induction. Differentiation. 2007;75:638–651. [PubMed]
16. Largaespada DA, Collier LS. Transposon-mediated mutagenesis in somatic cells: identification of transposon-genomic DNA junctions. Methods in molecular biology (Clifton, NJ. 2008;435:95–108. [PMC free article] [PubMed]
17. Warren M, Twohig M, Pier T, et al. Protein expression of matriptase and its cognate inhibitor HAI-1 in human prostate cancer: a tissue microarray and automated quantitative analysis. Appl Immunohistochem Mol Morphol. 2009;17:23–30. [PubMed]
18. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med. 2002;8:1323–1327. [PubMed]
19. Wild R, Ramakrishnan S, Sedgewick J, Griffioen AW. Quantitative assessment of angiogenesis and tumor vessel architecture by computer-assisted digital image analysis: effects of VEGF-toxin conjugate on tumor microvessel density. Microvasc Res. 2000;59:368–376. [PubMed]
20. Gallee MP, Visser-de Jong E, ten Kate FJ, Schroeder FH, Van der Kwast TH. Monoclonal antibody Ki-67 defined growth fraction in benign prostatic hyperplasia and prostatic cancer. J Urol. 1989;142:1342–1346. [PubMed]
21. Nowak SJ, Corces VG. Phosphorylation of histone H3: a balancing act between chromosome condensation and transcriptional activation. Trends Genet. 2004;20:214–220. [PubMed]
22. Geurts AM, Collier LS, Geurts JL, et al. Gene mutations and genomic rearrangements in the mouse as a result of transposon mobilization from chromosomal concatemers. PLoS Genet. 2006;2:e156. [PMC free article] [PubMed]
23. Carlson CM, Dupuy AJ, Fritz S, Roberg-Perez KJ, Fletcher CF, Largaespada DA. Transposon mutagenesis of the mouse germline. Genetics. 2003;165:243–256. [PubMed]
24. Mikkers H, Allen J, Knipscheer P, et al. High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat Genet. 2002;32:153–159. [PubMed]
25. Akagi K, Suzuki T, Stephens RM, Jenkins NA, Copeland NG. RTCGD: retroviral tagged cancer gene database. Nucleic Acids Res. 2004;32:D523–D527. [PMC free article] [PubMed]
26. Bijl J, Sauvageau M, Thompson A, Sauvageau G. High incidence of proviral integrations in the Hoxa locus in a new model of E2a-PBX1-induced B-cell leukemia. Genes Dev. 2005;19:224–233. [PubMed]
27. Liu X, Gorovsky MA. Mapping the 5' and 3' ends of Tetrahymena thermophila mRNAs using RNA ligase mediated amplification of cDNA ends (RLM-RACE) Nucleic Acids Res. 1993;21:4954–4960. [PMC free article] [PubMed]
28. Uren AG, Kool J, Berns A, van Lohuizen M. Retroviral insertional mutagenesis: past, present and future. Oncogene. 2005;24:7656–7672. [PubMed]
29. Uckert S, Oelke M, Stief CG, Andersson KE, Jonas U, Hedlund P. Immunohistochemical distribution of cAMP-and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol. 2006;49:740–745. [PubMed]
30. Uckert S, Kuthe A, Jonas U, Stief CG. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol. 2001;166:2484–2490. [PubMed]
31. Richter W, Jin SL, Conti M. Splice variants of the cyclic nucleotide phosphodiesterase PDE4D are differentially expressed and regulated in rat tissue. Biochem J. 2005;388:803–811. [PubMed]
32. Bolger GB, Erdogan S, Jones RE, et al. Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene. Biochem J. 1997;328(Pt 2):539–548. [PubMed]
33. Bolger G, Michaeli T, Martins T, et al. A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs. Mol Cell Biol. 1993;13:6558–6571. [PMC free article] [PubMed]
34. Nemoz G, Zhang R, Sette C, Conti M. Identification of cyclic AMP-phosphodiesterase variants from the PDE4D gene expressed in human peripheral mononuclear cells. FEBS Lett. 1996;384:97–102. [PubMed]
35. Ho SM, Tang WY, Belmonte de Frausto J, Prins GS. Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4. Cancer Res. 2006;66:5624–5632. [PMC free article] [PubMed]
36. Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004;6:1–6. [PMC free article] [PubMed]
37. Niles RM, Makarski JS, Kurtz MJ, Rutenburg AM. Inhibition of human prostatic epithelial cell replication by cAMP and selected analogs. Exp Cell Res. 1976;102:95–103. [PubMed]
38. Bang YJ, Pirnia F, Fang WG, et al. Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc Natl Acad Sci U S A. 1994;91:5330–5334. [PubMed]
39. Bang YJ, Kim SJ, Danielpour D, et al. Cyclic AMP induces transforming growth factor beta 2 gene expression and growth arrest in the human androgen-independent prostate carcinoma cell line PC-3. Proc Natl Acad Sci U S A. 1992;89:3556–3560. [PubMed]
40. Kim DH, Lerner A. Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia. Blood. 1998;92:2484–2494. [PubMed]
41. Zhang L, Murray F, Zahno A, et al. Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2008;105:19532–19537. [PubMed]
42. Weir BA, Woo MS, Getz G, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007;450:893–898. [PMC free article] [PubMed]
43. Nancarrow DJ, Handoko HY, Smithers BM, et al. Genome-wide copy number analysis in esophageal adenocarcinoma using high-density single-nucleotide polymorphism arrays. Cancer Res. 2008;68:4163–4172. [PubMed]
44. Dotto GP. Notch tumor suppressor function. Oncogene. 2008;27:5115–5123. [PMC free article] [PubMed]
45. Takeuchi T, Suzuki M, Kumagai J, Kamijo T, Sakai M, Kitamura T. Extracellular matrix dermatopontin modulates prostate cell growth in vivo. J Endocrinol. 2006;190:351–361. [PubMed]
46. Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res. 2002;62:2942–2950. [PubMed]
47. Fowler M, Borazanci E, McGhee L, et al. RUNX1 (AML-1) and RUNX2 (AML-3) cooperate with prostate-derived Ets factor to activate transcription from the PSA upstream regulatory region. J Cell Biochem. 2006;97:1–17. [PubMed]
48. Shou J, Ross S, Koeppen H, de Sauvage FJ, Gao WQ. Dynamics of notch expression during murine prostate development and tumorigenesis. Cancer Res. 2001;61:7291–7297. [PubMed]
49. Weiss-Messer E, Merom O, Adi A, et al. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells. Mol Cell Endocrinol. 2004;220:109–123. [PubMed]
50. Wu X, Li Y, Crise B, Burgess SM. Transcription start regions in the human genome are favored targets for MLV integration. Science. 2003;300:1749–1751. [PubMed]